NEXSTAR BROADCASTING GROUP, INC.(NXST) : Analyst Michael Senno tells salesforce raising his $30 NXST target to $42 to incorporate impact of more potential acquisitions in light of rapid consolidation trend. Notes despite influx of recent acquisitions, his analysis indicates group could still be early in consolidation phase. With multiple stations on the market, believes NXST could pursue additional M&A in near term. Estimates $300M debt-funded acquisition would drive EBITDA of ~$50M and $0.80 of accretive FCF on average for '13-'14.
STEMLINE THERAPEUTICS, INC.(STML) : Analyst Matthew Kaplan tells salesforce STML is in process of developing 2 therapeutic products, SL-401, SL-701 and targeting tumor bulk, cancer stem cells, which could enable co. to generate over $500M in annual rev. Says SL-401 is being developed to treat blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, SL-701 for adult glioblastoma multiforme, pediatric brainstem, non-brainstem glioma. Thinks breadth of clinical programs STML has planned will attract attention of possible partners, de-risk the product portfolio as more data generated.
FLIR SYSTEMS, INC.(FLIR) : Analyst Brian Gesuale tells salesforce believes volumes at FLIR can double from its current base by '15 as several catalysts drive adoption. Expects volumes from Mercedes to drive automotive units significantly higher thru YE, detector integration into Digimerge security cameras to begin to impact units later this year. While it may seem counterintuitive with sequester, believes Government unit is seeing solid orders with division backlog up y/y for four straight quarters and what is shaping up to be a strong Q2/Q3 '13. Has $33 price target.
The Right Stock At The Right Time®
Launch Smart Chart
